WO2002004522A3 - Bifunctional molecules and vectors complexed therewith for targeted gene delivery - Google Patents
Bifunctional molecules and vectors complexed therewith for targeted gene delivery Download PDFInfo
- Publication number
- WO2002004522A3 WO2002004522A3 PCT/EP2001/007878 EP0107878W WO0204522A3 WO 2002004522 A3 WO2002004522 A3 WO 2002004522A3 EP 0107878 W EP0107878 W EP 0107878W WO 0204522 A3 WO0204522 A3 WO 0204522A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- bifunctional molecules
- gene delivery
- targeted gene
- methods
- complexed therewith
- Prior art date
Links
- 230000001588 bifunctional effect Effects 0.000 title abstract 4
- 239000013598 vector Substances 0.000 title abstract 4
- 238000001476 gene delivery Methods 0.000 title abstract 2
- 238000000034 method Methods 0.000 abstract 3
- 102000018697 Membrane Proteins Human genes 0.000 abstract 2
- 108010052285 Membrane Proteins Proteins 0.000 abstract 2
- 239000002245 particle Substances 0.000 abstract 2
- 230000008685 targeting Effects 0.000 abstract 2
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 abstract 1
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 238000001415 gene therapy Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Saccharide Compounds (AREA)
Abstract
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002414272A CA2414272A1 (en) | 2000-07-10 | 2001-07-09 | Bifunctional molecules and vectors complexed therewith for targeted gene delivery |
EP01955340A EP1301541A2 (en) | 2000-07-10 | 2001-07-09 | Bifunctional molecules and vectors complexed therewith for targeted gene delivery |
AU2001277531A AU2001277531A1 (en) | 2000-07-10 | 2001-07-09 | Bifunctional molecules and vectors complexed therewith for targeted gene delivery |
IL15385301A IL153853A0 (en) | 2000-07-10 | 2001-07-09 | Bifunctional molecules and vectors complexed therewith for targeted gene delivery |
JP2002509384A JP2004502450A (en) | 2000-07-10 | 2001-07-09 | Bifunctional molecules for targeting gene delivery and vectors conjugated therewith |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US61301700A | 2000-07-10 | 2000-07-10 | |
US09/613,017 | 2000-07-10 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002004522A2 WO2002004522A2 (en) | 2002-01-17 |
WO2002004522A3 true WO2002004522A3 (en) | 2002-07-18 |
Family
ID=24455529
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2001/007878 WO2002004522A2 (en) | 2000-07-10 | 2001-07-09 | Bifunctional molecules and vectors complexed therewith for targeted gene delivery |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1301541A2 (en) |
JP (1) | JP2004502450A (en) |
AU (1) | AU2001277531A1 (en) |
CA (1) | CA2414272A1 (en) |
IL (1) | IL153853A0 (en) |
WO (1) | WO2002004522A2 (en) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7232899B2 (en) | 1996-09-25 | 2007-06-19 | The Scripps Research Institute | Adenovirus vectors, packaging cell lines, compositions, and methods for preparation and use |
US7329728B1 (en) | 1999-10-25 | 2008-02-12 | The Scripps Research Institute | Ligand activated transcriptional regulator proteins |
JP4563171B2 (en) | 2002-05-24 | 2010-10-13 | シェーリング コーポレイション | Neutralizing human anti-IGFR antibody |
CN1542132A (en) * | 2003-04-30 | 2004-11-03 | 上海新霁生物科技有限公司 | Highly expressed recombinant virus containing human constant region all-antibody gene and its use for treating tumor |
US7326567B2 (en) | 2003-11-12 | 2008-02-05 | Schering Corporation | Plasmid system for multigene expression |
AR046639A1 (en) | 2003-11-21 | 2005-12-14 | Schering Corp | ANTI-IGFR1 ANTIBODY THERAPEUTIC COMBINATIONS |
JP2008521907A (en) | 2004-12-03 | 2008-06-26 | シェーリング コーポレイション | Biomarkers for preselecting patients for anti-IGF1R treatment |
WO2006128679A2 (en) * | 2005-05-31 | 2006-12-07 | Martin Andreas Thurnher | Phosphatidylinositol composition and 3'-phosphorylated lysophosphatidylinositols in the treatment of cancer and autoimmune diseases |
WO2012021512A2 (en) | 2010-08-10 | 2012-02-16 | Ecole Polytechnique Federale De Lausanne | Erythrocyte-binding therapeutics |
US9517257B2 (en) | 2010-08-10 | 2016-12-13 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
US9850296B2 (en) | 2010-08-10 | 2017-12-26 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
CN106029874B (en) * | 2013-12-16 | 2020-09-15 | 北卡罗来纳-查佩尔山大学 | Depletion of plasmacytoid dendritic cells |
US10953101B2 (en) | 2014-02-21 | 2021-03-23 | École Polytechnique Fédérale De Lausanne (Epfl) | Glycotargeting therapeutics |
AU2015233084B2 (en) | 2014-02-21 | 2020-12-17 | Anokion Sa | Glycotargeting therapeutics |
US10946079B2 (en) | 2014-02-21 | 2021-03-16 | Ecole Polytechnique Federale De Lausanne | Glycotargeting therapeutics |
US10046056B2 (en) | 2014-02-21 | 2018-08-14 | École Polytechnique Fédérale De Lausanne (Epfl) | Glycotargeting therapeutics |
KR102380402B1 (en) | 2014-04-03 | 2022-03-31 | 아이쥐엠 바이오사이언스 인코포레이티드 | Modified j-chain |
EP3750918A1 (en) | 2015-01-20 | 2020-12-16 | IGM Biosciences, Inc. | Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof |
EP3355913A1 (en) | 2015-09-30 | 2018-08-08 | IGM Biosciences A/S | Binding molecules with modified j-chain |
DK3356401T3 (en) | 2015-09-30 | 2020-09-07 | Igm Biosciences Inc | BINDING MOLECULES WITH MODIFIED J-CHAIN |
CL2016000164A1 (en) * | 2016-01-21 | 2016-07-29 | Pontificia Universidad Católica De Chile | Monoclonal antibodies specific for the human adenovirus piii antigen (adv), produced and secreted by cellular hybridomas, useful for the detection and diagnosis of adv caused infection. |
EP3638296A1 (en) | 2017-06-16 | 2020-04-22 | The University Of Chicago | Compositions and methods for inducing immune tolerance |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998040508A1 (en) * | 1997-03-14 | 1998-09-17 | Selective Genetics, Inc. | Adenoviral vectors with modified tropism |
DE19849643A1 (en) * | 1998-10-29 | 2000-05-04 | Deutsches Krebsforsch | Antibodies to the AAV capsid that change cell tropism and method for directed gene transfer |
-
2001
- 2001-07-09 AU AU2001277531A patent/AU2001277531A1/en not_active Abandoned
- 2001-07-09 EP EP01955340A patent/EP1301541A2/en not_active Withdrawn
- 2001-07-09 JP JP2002509384A patent/JP2004502450A/en active Pending
- 2001-07-09 WO PCT/EP2001/007878 patent/WO2002004522A2/en not_active Application Discontinuation
- 2001-07-09 IL IL15385301A patent/IL153853A0/en unknown
- 2001-07-09 CA CA002414272A patent/CA2414272A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998040508A1 (en) * | 1997-03-14 | 1998-09-17 | Selective Genetics, Inc. | Adenoviral vectors with modified tropism |
DE19849643A1 (en) * | 1998-10-29 | 2000-05-04 | Deutsches Krebsforsch | Antibodies to the AAV capsid that change cell tropism and method for directed gene transfer |
Non-Patent Citations (5)
Title |
---|
E. LI ET AL.: "Production of functional antibodies generated in a nonlytic insect cell expression system.", PROTEIN EXPRESSION AND PURIFICATION, vol. 21, no. 1, February 2001 (2001-02-01), San Diego, CA, USA, pages 121 - 128, XP002198386 * |
H. HAISMA ET AL.: "Targeting of adenoviral vectors through a bispecific single-chain antibody.", CANCER GENE THERAPY, vol. 7, no. 6, June 2000 (2000-06-01), Norwalk, CT, USA, pages 901 - 904, XP001064497 * |
P. STEWART ET AL.: "Cryo-EM visualization of an exposed RGD epitope on adenovirus that escapes antibody neutralization,", THE EMBO JOURNAL, vol. 16, no. 6, 17 March 1997 (1997-03-17), Oxford, GB, pages 1189 - 1198, XP002198385 * |
S. WATKINS ET AL.: "Targeting adenovirus-mediated gene delivery with recombinant antibodies.", IMMUNOTECHNOLOGY, vol. 2, no. 4, 22 February 1996 (1996-02-22), Amsterdam, The Netherlands, pages 307, XP000672146 * |
S. WATKINS ET AL.: "The "adenobody" approach to viral targeting: specific and enhanced adenoviral gene delivery.", GENE THERAPY, vol. 4, no. 10, October 1997 (1997-10-01), Basingstoke, GB, pages 1004 - 1012, XP002106261 * |
Also Published As
Publication number | Publication date |
---|---|
AU2001277531A1 (en) | 2002-01-21 |
WO2002004522A2 (en) | 2002-01-17 |
IL153853A0 (en) | 2003-07-31 |
CA2414272A1 (en) | 2002-01-17 |
EP1301541A2 (en) | 2003-04-16 |
JP2004502450A (en) | 2004-01-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2002004522A3 (en) | Bifunctional molecules and vectors complexed therewith for targeted gene delivery | |
Kircheis et al. | Coupling of cell-binding ligands to polyethylenimine for targeted gene delivery | |
Pai et al. | The conformation of the poly (ethylene glycol) chain in mono-PEGylated lysozyme and mono-PEGylated human growth hormone | |
WO2004020595A3 (en) | Novel human polypeptides encoded by polynucleotides | |
Lim et al. | Tumor regression following intravenous administration of lactoferrin-and lactoferricin-bearing dendriplexes | |
NZ595896A (en) | Genetic products differentially expressed in tumors and the use thereof | |
WO2007073489A3 (en) | Molecules for gene delivery and gene therapy, and methods of use thereof | |
NZ504214A (en) | Recombination cloning using nucleic acids having recombination sites | |
WO2011013130A3 (en) | Cell-targeting nanoparticles comprising polynucleotide agents and uses thereof | |
WO1998035028A3 (en) | An oncolytic/immunogenic complementary-adenoviral vector system | |
WO2005115477A3 (en) | Non-natural ribonuclease conjugates as cytotoxic agents | |
WO2004013307A3 (en) | Compounds for targeting hepatocytes | |
AU4903101A (en) | Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof | |
WO2002029072A3 (en) | Targetting molecules for adenoviral vectors | |
WO2004074437A3 (en) | Compositions and methods for cancer immunotherapy | |
WO2003092579A3 (en) | Compositions and methods for treating cancer with an oncolytic viral agent | |
WO2004046332A3 (en) | Amplified genes involved in cancer | |
WO1999036545A3 (en) | Adenoviral vectors with modified capsid proteins | |
WO2004099422A3 (en) | Adenovirus particles with enhanced infectivity of dendritic cells and particles with decreased infectivity of hepatocytes | |
CA2265444A1 (en) | Tnf-beta-like protein for treating prostate cancer, and related nucleic acid molecules, pharmaceutical compositions and methods | |
WO2000069454A8 (en) | Suppression of endogenous igfbp-2 to inhibit cancer | |
WO2003044161A3 (en) | Gene amplification and overexpression in cancer | |
WO1999065506A3 (en) | Cancer therapy with indolicidin or cationic peptides and their polymer conjugates | |
WO1999002704A3 (en) | Dual specifically phosphatase and methods of use | |
Alamgir et al. | Bioreversible anionic cloaking enables intracellular protein delivery with ionizable lipid nanoparticles |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001955340 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001277531 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 153853 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 523555 Country of ref document: NZ Ref document number: 2414272 Country of ref document: CA |
|
WWP | Wipo information: published in national office |
Ref document number: 2001955340 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2001955340 Country of ref document: EP |